EZH2 as a Potential Target for NAFLD Therapy
Non-alcoholic fatty liver disease (NAFLD) is a complex disease that is affected by genetic predisposition and epigenetic modification. Deregulation of epigenetic pathways is now recognized as a frequent event in NAFLD, and understanding the mechanistic roles of these epigenetic factors may lead to n...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/22/8617 |
| _version_ | 1797547829104738304 |
|---|---|
| author | Hyun Jung Lim Mirang Kim |
| author_facet | Hyun Jung Lim Mirang Kim |
| author_sort | Hyun Jung Lim |
| collection | DOAJ |
| description | Non-alcoholic fatty liver disease (NAFLD) is a complex disease that is affected by genetic predisposition and epigenetic modification. Deregulation of epigenetic pathways is now recognized as a frequent event in NAFLD, and understanding the mechanistic roles of these epigenetic factors may lead to new strategies for NAFLD treatment. Enhancer of zeste homolog 2 (EZH2) catalyzes methylation on Lys 27 of histone H3, which leads to chromatin compaction and gene silencing. EZH2 regulates embryonic development and cell lineage determination and is related to many human diseases. Recent studies show that EZH2 has critical roles in liver development, homeostasis, and regeneration. Moreover, aberrant activation of EZH2 promotes NAFLD progression. Several EZH2 inhibitors have been developed and studied both in vitro and in clinical trials. In this review, we summarize our current understanding of the role of EZH2 in NAFLD and highlight its potential as a novel therapeutic target for NAFLD treatment. |
| first_indexed | 2024-03-10T14:49:51Z |
| format | Article |
| id | doaj.art-79b82841de1a48759f73f5f569caa18a |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T14:49:51Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-79b82841de1a48759f73f5f569caa18a2023-11-20T21:04:19ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-11-012122861710.3390/ijms21228617EZH2 as a Potential Target for NAFLD TherapyHyun Jung Lim0Mirang Kim1Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, KoreaPersonalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, KoreaNon-alcoholic fatty liver disease (NAFLD) is a complex disease that is affected by genetic predisposition and epigenetic modification. Deregulation of epigenetic pathways is now recognized as a frequent event in NAFLD, and understanding the mechanistic roles of these epigenetic factors may lead to new strategies for NAFLD treatment. Enhancer of zeste homolog 2 (EZH2) catalyzes methylation on Lys 27 of histone H3, which leads to chromatin compaction and gene silencing. EZH2 regulates embryonic development and cell lineage determination and is related to many human diseases. Recent studies show that EZH2 has critical roles in liver development, homeostasis, and regeneration. Moreover, aberrant activation of EZH2 promotes NAFLD progression. Several EZH2 inhibitors have been developed and studied both in vitro and in clinical trials. In this review, we summarize our current understanding of the role of EZH2 in NAFLD and highlight its potential as a novel therapeutic target for NAFLD treatment.https://www.mdpi.com/1422-0067/21/22/8617epigeneticsEZH2NAFLDNASHliver fibrosis |
| spellingShingle | Hyun Jung Lim Mirang Kim EZH2 as a Potential Target for NAFLD Therapy International Journal of Molecular Sciences epigenetics EZH2 NAFLD NASH liver fibrosis |
| title | EZH2 as a Potential Target for NAFLD Therapy |
| title_full | EZH2 as a Potential Target for NAFLD Therapy |
| title_fullStr | EZH2 as a Potential Target for NAFLD Therapy |
| title_full_unstemmed | EZH2 as a Potential Target for NAFLD Therapy |
| title_short | EZH2 as a Potential Target for NAFLD Therapy |
| title_sort | ezh2 as a potential target for nafld therapy |
| topic | epigenetics EZH2 NAFLD NASH liver fibrosis |
| url | https://www.mdpi.com/1422-0067/21/22/8617 |
| work_keys_str_mv | AT hyunjunglim ezh2asapotentialtargetfornafldtherapy AT mirangkim ezh2asapotentialtargetfornafldtherapy |